Authors : Radhika R, Beena Thomas, Ahmed Rafad, Jerin James, Mekha Monsi Chenthiyethu, Ruben Thomas Lal
DOI : 10.18231/j.ijirm.2022.005
Volume : 7
Issue : 1
Year : 2022
Page No : 16-20
Background: Tulobuterol Transdermal Drug Delivery (TTD) may be beneficial in COPD management. We aimed to study the effect of adding TTD to Triple Inhalation therapy (TI).
Materials and Methods: Participants on TTD and TI (TTD-TI cohort) and, TI only (TI cohort) were identified at the out-patient pharmacy counter. There was no loss to follow-up from 35 participants each enrolled in the cohorts. They were assessed with Modified British Medical Research Council questionnaire (modified Medical Research Council), COPD Control Questionnaire (CCQ) and COPD Assessment Test (CAT). The latter two were repeated at the end of six months. The change in score were compared with Mann-Whitney-U test.
Results: Mean age of participants in years was 63.4 and 65.7; 31% and 20% were females and rest were males in TTD-TI and TI cohorts respectively. All of them had modified Medical Research Council grade 2 or above. CCQ and CAT scores were comparable at baseline. Change in both CCQ and CAT scores were statistically significant between the cohorts (p<0> Conclusions: There would be a subjective improvement with addition of tulobuterol transdermal patch on to triple inhalation therapy for older persons with COPD.
Keywords: Tulobuterol Transdermal Patch, Long Acting Beta-2 Agonists, Chronic Obstructive Pulmonary Disease, Triple Inhalation Therapy, COPD Assessment Test